Aladdin Healthcare Technologies SE
- WKN: A12ULL
- ISIN: DE000A12ULL2
- Land: Deutschland
Nachricht vom 09.11.2020 | 07:59
Aladdin Healthcare Technologies discovers anti-osteoporosis nanomolar activity leads from natural compounds dataset with its Deep Learning Algorithms for drug discovery, validated by leading scientific publication 'European Journal of Medicinal Chemistry'
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Miscellaneous
Aladdin Healthcare Technologies discovers anti-osteoporosis nanomolar activity leads from natural compounds dataset with its Deep Learning Algorithms for drug discovery, validated by leading scientific publication "European Journal of Medicinal Chemistry"
- Innovative deep learning algorithms allow a successful virtual screening of anti-osteoporosis natural compounds
BERLIN/LONDON November 09, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, successfully validated its deep learning algorithms (P-SAMPNN) - Pre-trained Self-Attentive Message Passing Neural Network - for drug discovery. The European Journal of Medicinal Chemistry, a global impactful journal about medical chemistry, accepted and published Aladdin's and its partners' research paper on the discovery of highly potent anti-osteoporosis natural products by means of deep learning algorithms. The research paper has been partly published at https://www.sciencedirect.com/.
Working together with scientific renowned partners, such as the State Key Laboratory of Applied Microbiology Southern China and the School of Pharmaceutical Sciences, Sun Yat-sen University, Aladdin could put its innovative technology and long year expertise at service of drug discovery to run an Artificial Intelligence (AI) assisted virtual screening of a commercially available library about natural compounds to regulate osteoclastogenesis, which is the formation process of osteoclasts, the bone-resorbing cells. A too high activity of osteoclasts in the human body is actually one of the main causes of osteoporosis.
Aladdin's pre-trained deep learning method (P-SAMPNN) confirmed 5 from 10 selected hits through virtual screening of the natural products contained in the library. Among the confirmed hits, 2 compounds (AP-123/40765213 and AE-562/43462182) were actually the nanomolar inhibitors against osteoclastogenesis with a new scaffold. This work has proved that by integrating deep learning approaches with wet biological and chemical processes, the Pre-trained Self-Attentive Message Passing Neural Network (P-SAMPNN) is capable of expediting the drug discovery process and identifying nanomolar activity leads.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "The further validation of our innovative pre-trained deep learning model shows the high-end AI-technology capability of Aladdin. Validation processes proved that the P-SAMPNN model is significantly superior to other baseline models. By reaching this key milestone, we are continuing our path towards further breakthroughs in AI drug discovery."
Already in July this year, Aladdin announced the development of a new deep learning method for drug discovery with a superior performance, which was validated by the International Joint Conference on Artificial Intelligence (IJCAI), a world-leading organization for scientific purpose with focus on Artificial Intelligence (AI).
For further information:
Aladdin Healthcare Technologies Ltd.
|Company:||Aladdin Healthcare Technologies SE|
|Unter den Linden 10|
|Listed:||Regulated Market in Dusseldorf|
|EQS News ID:||1146362|
|End of News||DGAP News Service|
Aladdin Healthcare Technologies with new resea ...
Aladdin Healthcare Technologies SE: Preliminar ...
Aladdin Healthcare Technologies SE reports the ...
Aladdin Healthcare Technologies starts OTC Ent ...
Aladdin Healthcare Technologies SE
Event im Fokus
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
Kaufen: Aspermont Limited hat Turnaround abgeschlossen
Der AKTIONÄR News
18. September 07:00 Fashionette-CEO: „Wir haben ideale Voraussetzungen, um – profitabel – ...
18. September 07:00 JPMorgan und Bank of America: „Kauft Green-Tech-Aktien“ – diese ...
18. September 07:00 Top-Tipp Derivate: Wie geschmiert
18. September 06:00 Nach Plug Power, Nynomic, Nvidia und Enphase – das ist der nächste ...
17. September 21:18 Nasdaq 100 mit größtem Verlust seit Mai – der Tag an der Wall Street
News im Fokus
Vonovia SE: Vonovia verkauft Berliner Wohnungsbestände aus dem Zukunfts- und Sozialpakt Wohnen
17. September 2021, 12:40
Cantor Global Healthcare Conference Fireside Chat
30. September 2021
Original-Research: CR Capital AG (von First Berlin Equity Research GmbH): Buy
17. September 2021